1302 results about "Allergen" patented technology

The present invention relates to targeted polymerized liposomes for oral and / or mucosal delivery of vaccines, allergens and therapeutics. In particular, the present invention relates to polymerized liposomes which have been modified on their surface to contain a molecule or ligand which targets the polymerized liposome to a specific site or cell type. More particularly, the invention relates to the use of polymerized liposomes modified to contain a carbohydrate or lectin on their surface.

A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as a solution, dispersion, powder, or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector.

Described here are devices for altering the flow of air in a respiratory cavity such as the mouth and nostrils of the nose. These methods and devices may be useful for affecting a physiologic benefit in patients suffering from a variety of medical diseases, particularly those that may benefit from “pursed-lip” breathing and non-invasive ventilation, such as COPD, heart failure, sleep apnea, and other medical disorders. The devices are typically removable devices that may be placed over or in a respiratory cavity to increase resistance to airflow within the respiratory cavity. Resistance to expiration may be selectively increased relative to inspiration. Removable oral and removable nasal devices are described. Oral and nasal devices that filter inhaled airflow of debris and allergens are also provided. A nasal device that increases patency of the nares is also provided.

Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.

The present invention provides a specific filtration media which includes a substrate having cellulose fibers, bicomponent fibers, adhesion fibers, binder, and pressure sensitive adhesive. Also contemplated are fire retardant filtration media containing bicomponent fibers and polyester fibers or acrylic fibers, and optionally cellulose fibers. The cellulose fibers of the invention are pretreated with flame retardant, providing a beneficial material for filtration purposes.

This invention is for nasal adaptors for oral inhaler devices and methods of adapting an oral inhaler device with a nasal adaptor. The nasal adaptor of the present invention, in assembly with an oral metered dose aerosol inhaler converts an oral inhaler device to nasal delivery. The nasal adaptor in assembly with an oral inhaler device when in operation, simultaneously administers an inhalant to the nasal mucosa and down to the bronchial tree and lungs. In this manner a nasally delivered anti-inflammatory agent would travel down the same route as an allergen would—the nostril, nasal cavity, nasopharynx, trachea, bronchi and lung tissues.

The present invention includes methods and devices for providing safeguards to the access of certain substances. Some implementations provide alerts and / or other appropriate actions when substances are subject to spoilage or expiration. Some implementations provide responses to potentially dangerous combinations of substances. Other aspects of the invention involve determining the allergies of a user and providing a warning when allergens are, or recently have been, present. One preferred embodiment provides a smart medicine cabinet for helping to provide medication safely to a patient and to provide other related services.

The present invention includes methods and devices for providing safeguards to the access of certain substances. Some implementations provide alerts and / or other appropriate actions when substances are subject to spoilage or expiration. Some implementations provide responses to potentially dangerous combinations of substances. Other aspects of the invention involve determining the allergies of a user and providing a warning when allergens are, or recently have been, present. One preferred embodiment provides a smart medicine cabinet for helping to provide medication safely to a patient and to provide other related services.

The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to induce the immune response against the antigen. In a particular embodiment, the present invention relates to vaccines and compositions which induce a CTL response in a mammal comprising an antigen and all or a portion of a stress protein. In another embodiment, the invention relates to vaccines and compositions which induce an immune response to an influenza virus in a mammal comprising an antigen of the influenza virus and all or a portion of one or more stress proteins. The invention also relates to vaccines and compositions for inducing a CTL response to a tumor-associated antigen comprising a tumor-associated antigen and all or a portion of the stress protein. The invention also relates to vaccines and composition for suppressing allergic immune responses to allergens comprising an allergen and all or a portion of a stress protein.

The present invention relates to methods of sanitizing structures, buildings, passenger occupiable vehicles, and other enclosed or enclosable spaces. More particularly, the present invention relates to a method for killing and / or removing pests and their allergens, bacteria, viruses, fungi, molds, volatile organic compounds and other dangerous substances, from such enclosures.

This invention provides for an enzymatic cleaning composition that will reduce and remove allergens and perform general cleaning at the same time. The enzymatic cleaning composition comprises an enzyme and / or a bacterial spore substance capable of producing enzymes, a wetting agent, an odor-encapsulating agent, a neutralizing agent, a surfactant-encapsulating agent, an embrittling agent and water. The enzymatic composition is applied to carpets, upholstery, drapes and other fabrics, and hard surfaces. The applied composition dries and subsequently the allergens can be removed. Additionally, the present invention provides for a new and unique manner of delivery of the enzymatic composition.

The present invention relates to the use of calcium phosphate particles in formulation with allergens for allergic desensitization. Particularly, the invention relates to novel calcium phosphate core particles, particularly nano- and micron-sized particles, as allergen adjuvants and in compositions for inducing allergic desensitization. Methods of making such particles and to methods of inducing a specific immune response using the particles of this invention are also provided.

Provided is sampling and testing device for the detection of specific molds, allergens, viruses, bacteria, fungi, and other protein containing substances. Embodiments of the device include a sampling member slideably engaged with a base that contains a lateral flow strip adapted to detect specific analytes of interest. The sampling member defines a solvent reservoir that stores an elution solvent in a fluid-tight manner before the device is used to sample and test environmental surfaces. During slideable withdrawal of the sampling member from the base, the elution solvent stored in the reservoir is automatically released to a wick assembly of the sampling member. The wick assembly includes a wick adapted to receive, distribute, and retain the elution solvent. After a user samples an environmental surface for an analyte of interest with the elution solvent wetted wick, the sampling member is returned to the base where the wick contacts the lateral flow strip contained in the base. The wick transfers at least a portion of analyte and the elution solvent to the lateral flow strip for the calorimetric detection of specific allergens, viruses, bacteria, and other protein containing substances in the sample. The colorimetric results of the test are displayed through a window in the base.

Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-IBB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

The invention discloses a milk allergen test plate, which belongs to the gold immunochromatography detection. According to the milk allergen test plate disclosed by the invention, two ends of a PVC (polrvinyl chloride) base plate are respectively provided with a to-be-tested sample zone and an absorption zone. Colloidal gold mark antigens prepared by respectively marking colloidal gold into casein, beta lactoglobulin and alpha lactalbumin and mixing are orderly arranged between the sample zone to be tested and the absorption zone, and a nitrocellulose membrane is respectively provided with a detection zone coated with mixed milk allergen and a quality control zone coated with anti-beta lactoglobulin antibodies. In detection, color lines are formed in the detection zone and the quality contol zone when an immune complex is formed by specific milk antibodies contained in samples. If the samples do not contain specific milk antibodies, the detection zone does not display color, and only one color line is formed in the quality control zone. The milk allergen test plate disclosed by the invention with the design has the advantages of strong pertinence to the allergen detection, simplicity in operation, low cost and high sensitivity and the like, and can prevent the phenomenon of missed diagnosis in the single antibody detection. The milk allergen test plate is applied for rapidly screening patient allergic to milk, and is especially suitable for being used by primary medical treatment units.

A system and method for removing harmful biological and organic substances from an enclosure, vehicle or container includes protecting heat-sensitive articles within the enclosure. A plurality of temperature probes are positioned at predetermined locations within the enclosure. The air within the structure is heated to a predetermined temperature up to 400° F. to kill organisms and cause harmful substances in the enclosure to migrate into the ambient air. A negative pressure is created in the enclosure and the heated air carrying the harmful substances passed through a filter and is then vented from the enclosure and passed through a filter to remove the harmful substances from the heated air. The system effectively kills, molds, viruses and bacteria and reduces the levels of allergens and volatile organic compounds in the enclosure.

Methods of enhancing immune response to an immunogen in a subject are disclosed. Also disclosed are methods of reducing the sensitivity to an allergen in a subject. The methods comprise the administration of an immunomodulatory compound in specific dosing regimens that result in enhanced immune response or reduced sensitivity.

Assay devices comprising substrates functionalized to comprise probe species on multiple separate regions are provided. Ten thousand to a hundred thousand separate regions can be provided in a substrate of one square centimeter. The separate regions can comprise separate probe species, or in another embodiment, multiple different probe species can be present on each single functionalized region. The probe species are selected to be specific for binding to target species of interest in a sample. Methods and systems for making these devices are also provided. The devices are useful, for example for assaying molecules in a human sample that are reactive to a large number of different allergens placed on the substrate.

The present invention relates to methods of sanitizing structures, buildings, passenger occupiable vehicles, and other enclosed or enclosable spaces. More particularly, the present invention relates to a method for killing and / or removing pests and their allergens, bacteria, viruses, fungi, molds, volatile organic compounds and other dangerous substances, from such objects or enclosures.

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.

A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels.

This invention relates to a family of benzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy, asthma, or any diseases where IgE is pathogenic.

This invention relates to articles of manufacture containing liquid compositions of hypohalous acid or hypohalous acid salt for deactivating allergens and preventing diseases on hard surfaces, soft surfaces and in the air. The articles of manufacture contain usage instructions with health claims. This invention also includes methods of instructing the public and promoting the use of these compositions.

The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to induce the immune response against the antigen. In a particular embodiment, the present invention relates to vaccines and compositions which induce a CTL response in a mammal comprising an antigen and all or a portion of a stress protein. In another embodiment, the invention relates to vaccines and compositions which induce an immune response to an influenza virus in a mammal comprising an antigen of the influenza virus and all or a portion of one or more stress proteins. The invention also relates to vaccines and compositions for inducing a CTL response to a tumor-associated antigen comprising a tumor-associated antigen and all or a portion of the stress protein. The invention also relates to vaccines and composition for suppressing allergic immune responses to allergens comprising an allergen and all or a portion of a stress protein.

A mist generating system for a cleaning implement is adapted to generate a finely atomized liquid mist for suppressing dust, allergens, and other airborne particulates. The mist generating system can be adapted to fit many cleaning implements such as vacuum cleaners, wet extraction cleaners, floor mops, and dusters to suppress airborne dust and particulates generated during operation and the cleaning process.

Protective assemblies for zippers described may include a protective barrier for preventing migration of particles and / or organisms between opposite surfaces of the barrier. When a zipper assembly is brought to a closed position, a zipper slider may form a connection with the barrier resulting in an obstruction to block infiltration of small particles or organisms (e.g., bed bugs, allergens, dust mites, small particles, etc.). The barrier may be attached to an article, such as a padded material for use with a bedding / furniture cover. In some embodiments, a cover may be implemented to enclose a portion of the zipper slider. The barrier may include one or more padding materials for preventing migration of small particles or organisms past obstructions formed by the padding material(s).

The invention features methods and apparatus for the treatment of asthma patients. A controlled supply of breathable air delivered to a patient interface or mask (4) is controlled for patient comfort to maintain a steady pressure level in a range 2 to 4 cm H2O to accommodate patient respiration. The breathable air is cleaned by a high efficiency particulate arresting filter (10) to remove allergens from the air supply. The apparatus may be programmed to automatically detect asthma-related symptoms such as an asthma attack by analyzing the respiratory flow of the patient. In response to the detection of such an attack, the apparatus may provide an audible warning or if configured with a treatment delivery module (14A, 14B), the device may administer a therapeutically effective dose of a drug or substance, for example, a broncho-dilator, to alleviate the patient's breathing difficulty. Preferred mask designs allow for proper CO2 washout to accommodate the low pressures supplied to the mask and prevent asphyxia.

This invention relates to a family of benzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy, asthma, or any diseases where IgE is pathogenic.